An Observational, Retrospective Cohort Database Study to Assess the Safety of Boostrix (U.S. Formulation), a Reduced Tetanus, Diphtheria, Acellular Pertussis Vaccine (Tdap), Following Routine Immunization of Pregnant Women in the United States
Phase of Trial: Phase IV
Latest Information Update: 31 Oct 2018
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 07 Jun 2018 Planned End Date changed from 28 Feb 2020 to 30 Apr 2020.
- 07 Jun 2018 Planned primary completion date changed from 28 Feb 2020 to 30 Apr 2020.
- 02 May 2018 Planned End Date changed from 29 May 2020 to 28 Feb 2020.